drugset / Trial / NCT00055302
Arimidex in McCune Albright Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.
Timeline
- Start
- 2002-08
- Primary completion
- 2006-02
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |